Compare Tango Therapeutics Inc. (TNGX) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs VanEck Vietnam ETF — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while VanEck Vietnam ETF trades at $16.38 (market cap $465.30M). The key difference: Tango Therapeutics Inc. is far larger — about 8.1× VanEck Vietnam ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and VanEck Vietnam ETF for 52 Days on average.
| TNGX | VNM | |
|---|---|---|
Market Cap | $3.75B | $465.30M |
Volume | 9,619,106 | 633,123 |
Sector | Health | Sector/Thematic |
52-Week High | $32.90 | $19.80 |
52-Week Low | $7.50 | $16.34 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VNM stock trades at $16.53, down 0.3% with a bearish technical signal from moving averages. The ETF faces sector concentration risks in real estate and financials while trading at fair valuation. Recent news highlights Vietnam's potential US trade deal progress, though the fund has underperformed despite country growth prospects.
Near-term outlook remains cautious due to technical weakness and sector headwinds. Long-term exposure to Vietnam's growth offers potential, but investors face volatility from interest rate sensitivity and concentrated sector risks. The bearish technical setup suggests continued pressure on current price levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
